These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 15991041

  • 41. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients.
    Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, Khalili H, Jafarian A, Irajian H, Abdollahi A, Sadrai S.
    Exp Clin Transplant; 2012 Dec; 10(6):586-91. PubMed ID: 22770208
    [Abstract] [Full Text] [Related]

  • 42. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
    Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S.
    Ther Drug Monit; 2010 Dec; 32(6):778-81. PubMed ID: 20926996
    [Abstract] [Full Text] [Related]

  • 43. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO, García-Roca P, Romero-Tejeda EM, Reyes H, Medeiros M, Castañeda-Hernández G, Trocóniz IF.
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [Abstract] [Full Text] [Related]

  • 44. Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients.
    Alqahtani S, Alenazi M, Alsultan A, Alsarhani E.
    Saudi J Kidney Dis Transpl; 2021 Oct; 32(1):101-110. PubMed ID: 34145119
    [Abstract] [Full Text] [Related]

  • 45. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients.
    Willis C, Staatz CE, Tett SE.
    Ther Drug Monit; 2003 Apr; 25(2):158-66. PubMed ID: 12657909
    [Abstract] [Full Text] [Related]

  • 46. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F, Debord J, Undre N, Rousseau A, Marquet P.
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [Abstract] [Full Text] [Related]

  • 47. Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients.
    Chen L, Lu X, Tan G, Zhu L, Liu Y, Li M.
    Xenobiotica; 2020 Feb; 50(2):186-191. PubMed ID: 30995884
    [Abstract] [Full Text] [Related]

  • 48. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation.
    Riva N, Ibarra M, Parra-Guillen ZP, Galván ME, Pérez E, Trezeguet Renatti G, Cáceres Guido P, Lopez C, Licciardone N, Halac E, Dip M, Cruz A, Imventarza O, Buamscha D, Troconiz IF, Schaiquevich P.
    Br J Clin Pharmacol; 2023 Mar; 89(3):1115-1126. PubMed ID: 36222177
    [Abstract] [Full Text] [Related]

  • 49. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
    Ling J, Qian LX, Ding JJ, Jiao Z.
    Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
    [Abstract] [Full Text] [Related]

  • 50. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 51. Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients.
    Riff C, Debord J, Monchaud C, Marquet P, Woillard JB.
    Br J Clin Pharmacol; 2019 Aug; 85(8):1740-1750. PubMed ID: 30973981
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Pharmacokinetics of tacrolimus in liver transplant patients.
    Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, Mekki QA.
    Clin Pharmacol Ther; 1995 Mar; 57(3):281-90. PubMed ID: 7535213
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW, Lee SG, Hwang S, Kim KH, Kim WJ, Sin MH, Yoon YI, Tak EY.
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.